Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trevogrumab With or Without Garetosmab in Addition to Semaglutide in Patients With Obesity
NCT06299098Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of trevogrumab, garetosmab in obesity, sponsored by Regeneron Pharmaceuticals. Started Mar 2024; status: active, not recruiting.
02
Drugs
trevogrumabgaretosmab
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06299098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299098.